Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Sai Harisha Rajanala"'
Autor:
Sai Harisha Rajanala, Romina Ghale, Subhiksha Nandakumar, Kalyani Chadalavada, Gwo-Shu Mary Lee, Konrad H Stopsack, Yu Chen, Gouri J Nanjangud, Goutam Chakraborty, Philip W Kantoff
Publikováno v:
PLoS ONE, Vol 19, Iss 4, p e0301989 (2024)
Somatic Y chromosome loss in hematopoietic cells is associated with higher mortality in men. However, the status of the Y chromosome in cancer tissue is not fully known due to technical limitations, such as difficulties in labelling and sequencing DN
Externí odkaz:
https://doaj.org/article/9f025f8d20d746c0a246657541807f95
Autor:
Yuki Yoshikawa, Konrad H. Stopsack, Xin Victoria Wang, Yu‐Hui Chen, Ying Z. Mazzu, Foster Burton, Goutam Chakraborty, Sai Harisha Rajanala, Rahim Hirani, Subhiksha Nandakumar, Gwo‐Shu Mary Lee, David Frank, Elai Davicioni, Glenn Liu, Michael A. Carducci, Haruhito Azuma, Philip W. Kantoff, Christopher J. Sweeney
Publikováno v:
Molecular Oncology, Vol 16, Iss 22, Pp 3994-4010 (2022)
Loss of the histone demethylase KDM5D (lysine‐specific demethylase 5D) leads to in vitro resistance of prostate cancer cells to androgen deprivation therapy (ADT) with and without docetaxel. We aimed to define downstream drivers of the KDM5D effect
Externí odkaz:
https://doaj.org/article/f3e5c6df0fe14e4b96ddc7e70c0635e6
Autor:
Yuki Yoshikawa, Konrad H. Stopsack, Xin Victoria Wang, Yu‐Hui Chen, Ying Z. Mazzu, Foster Burton, Goutam Chakraborty, Sai Harisha Rajanala, Rahim Hirani, Subhiksha Nandakumar, Gwo‐Shu Mary Lee, David Frank, Elai Davicioni, Glenn Liu, Michael A. Carducci, Haruhito Azuma, Philip W. Kantoff, Christopher J. Sweeney
Publikováno v:
Molecular Oncology. 16:3994-4010
Loss of the histone demethylase KDM5D (lysine-specific demethylase 5D) leads to in vitro resistance of prostate cancer cells to androgen deprivation therapy (ADT) with and without docetaxel. We aimed to define downstream drivers of the KDM5D effect.
Autor:
Goutam Chakraborty, Subhiksha Nandakumar, Rahim Hirani, Bastien Nguyen, Konrad H. Stopsack, Christoph Kreitzer, Sai Harisha Rajanala, Romina Ghale, Ying Z. Mazzu, Naga Vara Kishore Pillarsetty, Gwo-Shu Mary Lee, Howard I. Scher, Michael J. Morris, Tiffany Traina, Pedram Razavi, Wassim Abida, Jeremy C. Durack, Stephen B. Solomon, Matthew G. Vander Heiden, Lorelei A. Mucci, Andreas G. Wibmer, Nikolaus Schultz, Philip W. Kantoff
Publikováno v:
Clin Cancer Res
Purpose: Oncogenic alterations of the PI3K/AKT pathway occur in >40% of patients with metastatic castration-resistant prostate cancer, predominantly via PTEN loss. The significance of other PI3K pathway components in prostate cancer is largely unknow
Autor:
Philip W. Kantoff, Nikolaus Schultz, Andreas G. Wibmer, Lorelei A. Mucci, Matthew G. Vander Heiden, Stephen B. Solomon, Jeremy C. Durack, Wassim Abida, Pedram Razavi, Tiffany Traina, Michael J. Morris, Howard I. Scher, Gwo-Shu Mary Lee, Naga Vara Kishore Pillarsetty, Ying Z. Mazzu, Romina Ghale, Sai Harisha Rajanala, Christoph Kreitzer, Konrad H. Stopsack, Bastien Nguyen, Rahim Hirani, Subhiksha Nandakumar, Goutam Chakraborty
Supplementary Table from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d3bb92d3643df0dcf9d9ec46df5f496
https://doi.org/10.1158/1078-0432.22487517.v1
https://doi.org/10.1158/1078-0432.22487517.v1
Autor:
Philip W. Kantoff, Nikolaus Schultz, Andreas G. Wibmer, Lorelei A. Mucci, Matthew G. Vander Heiden, Stephen B. Solomon, Jeremy C. Durack, Wassim Abida, Pedram Razavi, Tiffany Traina, Michael J. Morris, Howard I. Scher, Gwo-Shu Mary Lee, Naga Vara Kishore Pillarsetty, Ying Z. Mazzu, Romina Ghale, Sai Harisha Rajanala, Christoph Kreitzer, Konrad H. Stopsack, Bastien Nguyen, Rahim Hirani, Subhiksha Nandakumar, Goutam Chakraborty
Purpose:Oncogenic alterations of the PI3K/AKT pathway occur in >40% of patients with metastatic castration-resistant prostate cancer, predominantly via PTEN loss. The significance of other PI3K pathway components in prostate cancer is largely unknown
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f53b24779ecb04e264a00e6f5f38cc7
https://doi.org/10.1158/1078-0432.c.6532536
https://doi.org/10.1158/1078-0432.c.6532536
Autor:
Philip W. Kantoff, Nikolaus Schultz, Andreas G. Wibmer, Lorelei A. Mucci, Matthew G. Vander Heiden, Stephen B. Solomon, Jeremy C. Durack, Wassim Abida, Pedram Razavi, Tiffany Traina, Michael J. Morris, Howard I. Scher, Gwo-Shu Mary Lee, Naga Vara Kishore Pillarsetty, Ying Z. Mazzu, Romina Ghale, Sai Harisha Rajanala, Christoph Kreitzer, Konrad H. Stopsack, Bastien Nguyen, Rahim Hirani, Subhiksha Nandakumar, Goutam Chakraborty
Supplementary Figure from The Impact of PIK3R1 Mutations and Insulin–PI3K–Glycolytic Pathway Regulation in Prostate Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::073030da76f089c6a152bc46fdb25d7e
https://doi.org/10.1158/1078-0432.22487526
https://doi.org/10.1158/1078-0432.22487526
Autor:
Lina E. Jehane, YuRou Liao, Huiyong Zhao, Yu Chen, Anuradha Gopalan, Sai Harisha Rajanala, Gwo-Shu Mary Lee, Goutam Chakraborty, Ruifang Li, Subhiksha Nandakumar, Ying Z. Mazzu, Richard Koche, Gouri Nanjangud, Travis Gerke, Philip W. Kantoff
Publikováno v:
Oncogene. 41:671-682
Chromosome 8q gain is associated with poor clinical outcomes in prostate cancer, but the underlying biological mechanisms remain to be clarified. CSN5, a putative androgen receptor (AR) partner that is located on chromosome 8q, is the key subunit of
Autor:
null Yuki Yoshikawa, null Konrad H. Stopsack, null Xin Victoria Wang, null Yu‐Hui Chen, null Ying Z. Mazzu, null Foster Burton, null Goutam Chakraborty, null Sai Harisha Rajanala, null Rahim Hirani, null Subhiksha Nandakumar, null Gwo‐Shu Mary Lee, null David Frank, null Elai Davicioni, null Glenn Liu, null Michael A. Carducci, null Haruhito Azuma, null Philip W. Kantoff, null Christopher J. Sweeney
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26eeb6fe81730cad59f6eb4bd26a1d0f
https://doi.org/10.1002/1878-0261.13314/v2/response1
https://doi.org/10.1002/1878-0261.13314/v2/response1
Autor:
Subhiksha Nandakumar, Sai Harisha Rajanala, Lina E. Jehane, Nikolaus Schultz, Philip W. Kantoff, Ying Z. Mazzu, Gwo-Shu Mary Lee, Lorelei A. Mucci, Bastien Nguyen, Romina Ghale, Goutam Chakraborty, Rahim Hirani
Publikováno v:
Cancer Research. 81:2498-2498
Metastatic castration-resistant metastatic prostate cancer (mCRPC) is incurable. Recent comprehensive genomic characterization of localized and metastatic prostate cancer has identified a long tail of oncogenic driver mutations and demonstrated recur